[EN] AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTIEN KINASE [FR] INHIBITEURS À BASE DE TRIAZOLOPYRAZOLE, TRIAZOLOTHIADIAZOLE DE LA PROTÉINE KINASE C-MET
[EN] INHIBITORS OF C-MET PROTEIN KINASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C-MET
申请人:VERTEX PHARMA
公开号:WO2010138673A1
公开(公告)日:2010-12-02
The present invention relates to compounds of formula (I), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
申请人:Vertex Pharmaceuticals Incorporated
公开号:US08269012B2
公开(公告)日:2012-09-18
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
Substituted pyrazole inhibitors of c-Met protein kinase
申请人:Vertex Pharmaceuticals Incorporated
公开号:US08269013B2
公开(公告)日:2012-09-18
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.
AMINOPYRAZOLE TRIAZOLOTHIADIAZOLE INHIBITORS OF C-MET PROTEIN KINASE
申请人:Lauffer David
公开号:US20130018072A1
公开(公告)日:2013-01-17
The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.